SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Marcella PreteElvira FavoinoGiacomo CatacchioVito RacanelliFederico PerosaPublished in: International journal of molecular sciences (2020)
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of its highly contagious nature, the great number of patients requiring intensive care therapy, and the high fatality rate. In the absence of specific antiviral drugs, passive prophylaxis, or a vaccine, the treatment aim in these patients is to prevent the potent virus-induced inflammatory stimuli from leading to the acute respiratory distress syndrome (ARDS), which has a severe prognosis. Here, the mechanism of action and the rationale for employing immunological strategies, which range from traditional chemically synthesized drugs, anti-cytokine antibodies, human immunoglobulin for intravenous use, to vaccines, are reviewed.
Keyphrases
- sars cov
- acute respiratory distress syndrome
- end stage renal disease
- newly diagnosed
- ejection fraction
- extracorporeal membrane oxygenation
- global health
- chronic kidney disease
- public health
- emergency department
- clinical trial
- respiratory syndrome coronavirus
- oxidative stress
- endothelial cells
- healthcare
- coronavirus disease
- stem cells
- patient reported outcomes
- combination therapy
- drug induced